Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $39.18

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $39.1818.

A number of analysts have recently commented on the company. Chardan Capital upped their price target on Stoke Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, January 5th. JPMorgan Chase & Co. upped their target price on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Monday, November 3rd. UBS Group set a $50.00 price target on shares of Stoke Therapeutics in a research report on Monday, December 15th. BTIG Research restated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th.

Insider Activity

In related news, Director Edward M. Md Kaye sold 13,430 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $32.27, for a total value of $433,386.10. Following the completion of the transaction, the director directly owned 49,124 shares in the company, valued at approximately $1,585,231.48. The trade was a 21.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 8,785 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $31.29, for a total transaction of $274,882.65. Following the completion of the transaction, the general counsel directly owned 15,809 shares in the company, valued at approximately $494,663.61. The trade was a 35.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 58,302 shares of company stock worth $1,826,430 in the last 90 days. Corporate insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Harbour Investments Inc. lifted its stake in Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after acquiring an additional 898 shares in the last quarter. Generali Investments Management Co LLC acquired a new position in Stoke Therapeutics during the third quarter worth $41,000. BNP Paribas Financial Markets increased its stake in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter. Finally, Osaic Holdings Inc. grew its holdings in shares of Stoke Therapeutics by 263.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock valued at $85,000 after acquiring an additional 5,427 shares in the last quarter.

Stoke Therapeutics Stock Down 1.0%

Shares of Stoke Therapeutics stock opened at $31.89 on Tuesday. The business has a fifty day simple moving average of $31.59 and a 200 day simple moving average of $26.71. The stock has a market cap of $1.82 billion, a PE ratio of 47.60 and a beta of 1.10. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $38.69.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.